ANTIBODY PERSISTENCE 12 MONTHS AFTER A BOOSTER DOSE OF MENINGOCOCCAL-C CONJUGATED VACCINE IN THE SECOND YEAR OF LIFE
| Autor: | M. Victoria Planelles-Cantarino, Jose M. Baldo-Torrenti, M. Victoria Gutierrez-Gimeno, Angels Jubert-Rosich, Isabel Úbeda-Sansano, Joan Puig-Barberà, Javier Díez-Domingo |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Microbiology (medical)
Time Factors Immunization Secondary Meningococcal Vaccines Booster dose Meningococcal disease complex mixtures Tetanus Toxoid medicine Humans Seroconversion Booster (rocketry) Tetanus business.industry Polysaccharides Bacterial Vaccination Toxoid Infant medicine.disease Antibodies Bacterial Meningococcal Infections Titer Infectious Diseases Child Preschool Pediatrics Perinatology and Child Health Immunology business |
| Zdroj: | Pediatric Infectious Disease Journal. 29:768-770 |
| ISSN: | 0891-3668 |
| Popis: | We report on the results of the 12-month follow-up of children aged 14 to 18 months who received primary and booster vaccinations with either a meningococcal-C vaccine conjugated to tetanus toxoid or CRM197. Seroprotection (92.8%) and geometric mean titers/serum bactericidal activity (410.5; 95% CI: 273.4-616.3) were higher in children receiving the meningococcal serogroup C tetanus toxoid conjugate, compared with 61.5% and serum bactericidal antibody geometric mean titer of 45.1 (95% CI: 28.5-71.3) when MenC-CRM197 conjugate was used. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|